These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 15679288)

  • 1. Angiotensin receptor blockers. Applications beyond hypertension.
    Jacobs TF; Ramsey LA
    Adv Nurse Pract; 2005 Jan; 13(1):27-30. PubMed ID: 15679288
    [No Abstract]   [Full Text] [Related]  

  • 2. [AT1 receptor antagonist lorsartan and organ protection. Managing hypertension a different way].
    MMW Fortschr Med; 2006 Mar; 148(13):48-9. PubMed ID: 16642707
    [No Abstract]   [Full Text] [Related]  

  • 3. Mechanisms for the clinical benefits of angiotensin II receptor blockers.
    Schmieder RE
    Am J Hypertens; 2005 May; 18(5 Pt 1):720-30. PubMed ID: 15882557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure.
    Aksnes TA; Flaa A; Strand A; Kjeldsen SE
    J Hypertens; 2007 Jan; 25(1):15-23. PubMed ID: 17143167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin-receptor blockers: benefits beyond lowering blood pressure.
    Silverstein RL; Ram CV
    Cleve Clin J Med; 2005 Sep; 72(9):825-32. PubMed ID: 16193831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality.
    Abassi Z; Winaver J; Feuerstein GZ
    Biochem Pharmacol; 2009 Oct; 78(8):933-40. PubMed ID: 19477166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Have angiotensin receptor blockers lived up to expectations?
    Fitchett D
    Can J Cardiol; 2005 May; 21(7):569-75. PubMed ID: 15940354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hypertension and the heart].
    Wachtell K; Andersen NH; Svendsen TL
    Ugeskr Laeger; 2009 Jun; 171(25):2113-6. PubMed ID: 19671394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effects of angiotensin II type 1 receptor blocker at an advanced stage of hypertensive diastolic heart failure.
    Nishio M; Sakata Y; Mano T; Yoshida J; Ohtani T; Takeda Y; Miwa T; Masuyama T; Yamamoto K; Hori M
    J Hypertens; 2007 Feb; 25(2):455-61. PubMed ID: 17211254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal and stroke protection in hypertensive patients at CV risk.
    Cardiovasc J Afr; 2007; 18(5):337, 340. PubMed ID: 17985036
    [No Abstract]   [Full Text] [Related]  

  • 11. Renoprotection of angiotensin receptor blockers: beyond blood pressure lowering.
    Miyata T; van Ypersele de Strihou C
    Nephrol Dial Transplant; 2006 Apr; 21(4):846-9. PubMed ID: 16476717
    [No Abstract]   [Full Text] [Related]  

  • 12. [New effective dosage of valsartan. High dosage--effective against high blood pressure].
    MMW Fortschr Med; 2007 Nov; 149(46):52-3. PubMed ID: 18069195
    [No Abstract]   [Full Text] [Related]  

  • 13. Left-ventricular hypertrophy and coronary artery disease.
    Pierdomenico SD
    Am J Hypertens; 2007 Oct; 20(10):1036-7. PubMed ID: 17903684
    [No Abstract]   [Full Text] [Related]  

  • 14. Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?
    van de Wal RM; van Veldhuisen DJ; van Gilst WH; Voors AA
    Eur Heart J; 2005 Nov; 26(22):2361-7. PubMed ID: 16105846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II antagonists--therapeutic benefits spanning the cardiovascular disease continuum from hypertension to heart failure and diabetic nephropathy.
    Ribeiro AB
    Curr Med Res Opin; 2006 Jan; 22(1):1-16. PubMed ID: 16393425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antihypertensive therapy: risk stratification in diabetes and cardiac diseases].
    Baumgart P
    MMW Fortschr Med; 2006 Mar; 148(11):57, 59-60. PubMed ID: 16612965
    [No Abstract]   [Full Text] [Related]  

  • 17. Diabetic nephropathy: common questions.
    Thorp ML
    Am Fam Physician; 2005 Jul; 72(1):96-9. PubMed ID: 16035688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complications of hypertension and the role of angiotensin receptor blockers in hypertension trials.
    Flaa A; Aksnes TA; Strand A; Kjeldsen SE
    Expert Rev Cardiovasc Ther; 2007 May; 5(3):451-61. PubMed ID: 17489670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin-II receptor blockers for hypertension and heart failure: quality of life and outcomes.
    Weber MA
    Manag Care Interface; 2005 Feb; 18(2):47-54. PubMed ID: 15766065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.